CRISPR Therapeutics AG (CRSP) Other Non-Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Other Non-Current Liabilities across 12 years of filings, most recently posting $6.2 million for Q2 2026.

• In Q2 2026, Other Non-Current Liabilities rose 38.99% year-over-year to $6.2 million; the TTM figure through Jun 2026 stood at $6.2 million (up 38.99% YoY), while the FY2025 annual figure was $6.1 million, up 78.34% from the prior year.
• Other Non-Current Liabilities came in at $6.2 million for Q2 2026 at CRISPR Therapeutics AG, up from $5.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $7.3 million in Q1 2022 to a low of $958000.0 in Q4 2023.
• Average Other Non-Current Liabilities over 5 years is $4.9 million, with a median of $5.4 million recorded in 2022.
• Year-over-year, Other Non-Current Liabilities plunged 83.95% in 2023 and surged 259.5% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $6.0 million in 2022, then sank by 83.95% to $958000.0 in 2023, then surged by 259.5% to $3.4 million in 2024, then soared by 78.34% to $6.1 million in 2025, then increased by 1.29% to $6.2 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $6.2 million in Q2 2026, $5.9 million in Q1 2026, and $6.1 million in Q4 2025.